G007-LK | 1380672-82-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: G007-LK
• 英文别名: 4-{5-[(1E)-2-[4-(2-chlorophenyl)-5-(5-methanesulfonylpyridin-2-yl)-1,2,4-triazol-3-yl]ethenyl]-1,3,4-oxadiazol-2-yl}benzonitrile；4-[5-[2-[4-(2-chlorophenyl)-5-(5-methylsulfonylpyridin-2-yl)-1,2,4-triazol-3-yl]ethenyl]-1,3,4-oxadiazol-2-yl]benzonitrile
• CAS: 1380672-82-1
• 化学式: C₂₅H₁₆ClN₇O₃S
• 分子量: 529.966
• InChiKey: HIWVLHPKZNBSBE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  37
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  149
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  G007-LK 在 溴 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 以77%的产率得到4-(5-{1,2-dibromo-2-[4-(2-chloro-phenyl)-5-(5-methanesulfonyl-pyridin-2-yl)-4H-[1,2,4]triazol-3-yl]-ethyl}-[1,3,4]oxadiazol-2-yl)-benzonitrile
  参考文献：
  名称：

  [EN] TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS
  [FR] DÉRIVÉS DE TRIAZOLE EN TANT QU'INHIBITEURS DE LA VOIE DE SIGNALISATION WNT

  摘要：

  本发明涉及公式(I)的化合物，其制备方法，含有这些化合物的药物配方以及它们在治疗中的应用：这些化合物在治疗和/或预防受Wnt途径信号过度激活和核β-连接蛋白存在增加影响的疾病或病症方面具有特殊用途。例如，这些化合物可用于预防和/或延缓肿瘤细胞和转移的增殖，例如结肠癌等癌症。

  公开号：

  WO2012076898A1

文献信息

• TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS
  申请人：Holsworth Daniel

  公开号：US20140031374A1

  公开（公告）日：2014-01-30

  The present invention relates to compounds of formula (I), to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy: Such compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the Wnt pathway and increased presence of nuclear β-catenin. For example, these may be used in preventing and/or retarding proliferation of tumor cells and metastasis, for example carcinomas such as colon carcinomas.

  本发明涉及式(I)的化合物、制备它们的方法、含有这种化合物的药物配方以及它们在治疗中的应用。这些化合物在治疗和/或预防受Wnt通路信号过度激活和核β-连环蛋白存在增加影响的疾病或病症方面具有特殊用途。例如，它们可用于预防和/或延缓肿瘤细胞和转移的增殖，例如结肠癌等癌症。
• Triazole derivatives as Wnt signaling pathway inhibitors
  申请人：Holsworth Daniel

  公开号：US09096587B2

  公开（公告）日：2015-08-04

  The present invention relates to compounds of formula (I), to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy: Such compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the Wnt pathway and increased presence of nuclear β-catenin. For example, these may be used in preventing and/or retarding proliferation of tumor cells and metastasis, for example carcinomas such as colon carcinomas.

  本发明涉及式(I)的化合物，其制备过程，含有此类化合物的制药配方以及它们在治疗中的应用：这些化合物在治疗和/或预防受Wnt通路信号过度激活和核β-连接蛋白存在增加影响的疾病或病症方面发挥特殊作用。例如，它们可用于预防和/或延缓肿瘤细胞和转移的增殖，例如结肠癌等癌症。
• Antiviral axin stabilizer
  申请人：The Board of Regents for Oklahoma State University

  公开号：US10064862B2

  公开（公告）日：2018-09-04

  Methods and compositions for preventing and/or treating viral infections are provided. The methods involve administering an agent that stabilizes or enhances Axin1 activity, e.g. and agent that inhibits tankyrase. Administration of the agent stimulates or increases interferon activity, thereby preventing or lessening at least one symptom of virus infection. The virus infection may be caused by a respiratory virus such as influenza vims.

  提供了预防和/或治疗病毒感染的方法和组合物。这些方法包括施用稳定或增强 Axin1 活性的制剂，例如抑制 tankyrase 的制剂。给药可刺激或增加干扰素活性，从而预防或减轻病毒感染的至少一种症状。病毒感染可由呼吸道病毒引起，如流感病毒。
• Methods of cancer treatment
  申请人：K-Gen, Inc.

  公开号：US10722484B2

  公开（公告）日：2020-07-28

  This present disclosure is directed to a method of treating a subject with cancer with a combination of a protein kinase C (PKC) activator and a second therapeutic agent.

  本公开涉及一种用蛋白激酶 C (PKC) 激活剂和第二种治疗剂组合治疗癌症患者的方法。
• ANTIVIRAL AXIN STABLIZER
  申请人：The Board of Regents for Oklahoma State University

  公开号：US20170065587A1

  公开（公告）日：2017-03-09

  Methods and compositions for preventing and/or treating viral infections are provided. The methods involve administering an agent that stabilizes or enhances Axin1 activity, e.g. and agent that inhibits tankyrase. Administration of the agent stimulates or increases interferon activity, thereby preventing or lessening at least one symptom of virus infection. The virus infection may be caused by a respiratory virus such as influenza vims.